Cargando…
Indole Inhibitors of MMP-13 for Arthritic Disorders
[Image: see text] Here, we described the design, by fragment merging and multiparameter optimization, of selective MMP-13 inhibitors that display an appropriate balance of potency and physicochemical properties to qualify as tool compounds suitable for in vivo testing. Optimization of potency was gu...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319936/ https://www.ncbi.nlm.nih.gov/pubmed/34337203 http://dx.doi.org/10.1021/acsomega.1c01320 |
_version_ | 1783730552095899648 |
---|---|
author | Taylor, Steven J. Abeywardane, Asitha Liang, Shuang Xiong, Zhaoming Proudfoot, John R. Farmer, Bennett Sandy Gao, Donghong A. Heim-Riether, Alexander Smith-Keenan, Lana Louise Muegge, Ingo Yu, Yang Zhang, Qiang Souza, Donald Panzenbeck, Mark Goldberg, Daniel Hill-Drzewi, Melissa Margarit, Mariana Collins, Brandon Li, John Xiang Zuvela-Jelaska, Ljiljana Li, Jun Farrow, Neil A. |
author_facet | Taylor, Steven J. Abeywardane, Asitha Liang, Shuang Xiong, Zhaoming Proudfoot, John R. Farmer, Bennett Sandy Gao, Donghong A. Heim-Riether, Alexander Smith-Keenan, Lana Louise Muegge, Ingo Yu, Yang Zhang, Qiang Souza, Donald Panzenbeck, Mark Goldberg, Daniel Hill-Drzewi, Melissa Margarit, Mariana Collins, Brandon Li, John Xiang Zuvela-Jelaska, Ljiljana Li, Jun Farrow, Neil A. |
author_sort | Taylor, Steven J. |
collection | PubMed |
description | [Image: see text] Here, we described the design, by fragment merging and multiparameter optimization, of selective MMP-13 inhibitors that display an appropriate balance of potency and physicochemical properties to qualify as tool compounds suitable for in vivo testing. Optimization of potency was guided by structure-based insights, specifically to replace an ester moiety and introduce polar directional hydrogen bonding interactions in the core of the molecule. By introducing polar enthalpic interactions in this series of inhibitors, the overall beneficial physicochemical properties were maintained. These physicochemical properties translated to excellent drug-like properties beyond potency. In a murine model of rheumatoid arthritis, treatment of mice with selective inhibitors of MMP-13 resulted in a statistically significant reduction in the mean arthritic score vs control when dosed over a 14 day period. |
format | Online Article Text |
id | pubmed-8319936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-83199362021-07-30 Indole Inhibitors of MMP-13 for Arthritic Disorders Taylor, Steven J. Abeywardane, Asitha Liang, Shuang Xiong, Zhaoming Proudfoot, John R. Farmer, Bennett Sandy Gao, Donghong A. Heim-Riether, Alexander Smith-Keenan, Lana Louise Muegge, Ingo Yu, Yang Zhang, Qiang Souza, Donald Panzenbeck, Mark Goldberg, Daniel Hill-Drzewi, Melissa Margarit, Mariana Collins, Brandon Li, John Xiang Zuvela-Jelaska, Ljiljana Li, Jun Farrow, Neil A. ACS Omega [Image: see text] Here, we described the design, by fragment merging and multiparameter optimization, of selective MMP-13 inhibitors that display an appropriate balance of potency and physicochemical properties to qualify as tool compounds suitable for in vivo testing. Optimization of potency was guided by structure-based insights, specifically to replace an ester moiety and introduce polar directional hydrogen bonding interactions in the core of the molecule. By introducing polar enthalpic interactions in this series of inhibitors, the overall beneficial physicochemical properties were maintained. These physicochemical properties translated to excellent drug-like properties beyond potency. In a murine model of rheumatoid arthritis, treatment of mice with selective inhibitors of MMP-13 resulted in a statistically significant reduction in the mean arthritic score vs control when dosed over a 14 day period. American Chemical Society 2021-07-19 /pmc/articles/PMC8319936/ /pubmed/34337203 http://dx.doi.org/10.1021/acsomega.1c01320 Text en © 2021 The Authors. Published by American Chemical Society Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Taylor, Steven J. Abeywardane, Asitha Liang, Shuang Xiong, Zhaoming Proudfoot, John R. Farmer, Bennett Sandy Gao, Donghong A. Heim-Riether, Alexander Smith-Keenan, Lana Louise Muegge, Ingo Yu, Yang Zhang, Qiang Souza, Donald Panzenbeck, Mark Goldberg, Daniel Hill-Drzewi, Melissa Margarit, Mariana Collins, Brandon Li, John Xiang Zuvela-Jelaska, Ljiljana Li, Jun Farrow, Neil A. Indole Inhibitors of MMP-13 for Arthritic Disorders |
title | Indole Inhibitors of MMP-13 for Arthritic Disorders |
title_full | Indole Inhibitors of MMP-13 for Arthritic Disorders |
title_fullStr | Indole Inhibitors of MMP-13 for Arthritic Disorders |
title_full_unstemmed | Indole Inhibitors of MMP-13 for Arthritic Disorders |
title_short | Indole Inhibitors of MMP-13 for Arthritic Disorders |
title_sort | indole inhibitors of mmp-13 for arthritic disorders |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319936/ https://www.ncbi.nlm.nih.gov/pubmed/34337203 http://dx.doi.org/10.1021/acsomega.1c01320 |
work_keys_str_mv | AT taylorstevenj indoleinhibitorsofmmp13forarthriticdisorders AT abeywardaneasitha indoleinhibitorsofmmp13forarthriticdisorders AT liangshuang indoleinhibitorsofmmp13forarthriticdisorders AT xiongzhaoming indoleinhibitorsofmmp13forarthriticdisorders AT proudfootjohnr indoleinhibitorsofmmp13forarthriticdisorders AT farmerbennettsandy indoleinhibitorsofmmp13forarthriticdisorders AT gaodonghonga indoleinhibitorsofmmp13forarthriticdisorders AT heimrietheralexander indoleinhibitorsofmmp13forarthriticdisorders AT smithkeenanlanalouise indoleinhibitorsofmmp13forarthriticdisorders AT mueggeingo indoleinhibitorsofmmp13forarthriticdisorders AT yuyang indoleinhibitorsofmmp13forarthriticdisorders AT zhangqiang indoleinhibitorsofmmp13forarthriticdisorders AT souzadonald indoleinhibitorsofmmp13forarthriticdisorders AT panzenbeckmark indoleinhibitorsofmmp13forarthriticdisorders AT goldbergdaniel indoleinhibitorsofmmp13forarthriticdisorders AT hilldrzewimelissa indoleinhibitorsofmmp13forarthriticdisorders AT margaritmariana indoleinhibitorsofmmp13forarthriticdisorders AT collinsbrandon indoleinhibitorsofmmp13forarthriticdisorders AT lijohnxiang indoleinhibitorsofmmp13forarthriticdisorders AT zuvelajelaskaljiljana indoleinhibitorsofmmp13forarthriticdisorders AT lijun indoleinhibitorsofmmp13forarthriticdisorders AT farrowneila indoleinhibitorsofmmp13forarthriticdisorders |